Disease activity score for still's disease.
CRP
Fever
Physician VAS
Still’s Disease Activity Score (SDAS)
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
27
06
2024
accepted:
29
08
2024
revised:
23
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
aheadofprint
Résumé
To develop the Still's Disease Activity Score (SDAS). We used data from the prospective adult-onset Still's disease cohort study and evaluated the disease activity. An expert group selected the most frequent, reproducible, and objective variables significantly modified in statistical analysis when comparing patients in the active group and in the remission group. These criteria were weighted to design the Still's Disease Activity Score (SDAS). The Delphi method was used to appreciate the level of disease activity. Total SDAS was calculated for each patient and compared to final consensus experts. At the diagnosis, all patients had an active disease (n = 80), while 48 patients were in remission at 6 months. The SDAS criteria were weighted as follows: fever ≥ 38.5 °C (1 point), rash (1 point), joint involvement (arthralgia: 1 point, swollen joints count "SJC": 1-3 SJC: 2 points, ≥ 4 SJC: 3 points), physician global assessment VAS ≥ 5/10 or a raise in physician VAS ≥ 2/10 (3 points), patient VAS ≥ 5 or a raise in patient VAS ≥ 2/10 (1 point), and CRP (> 10 mg/l: 1 point, ≥ 100 mg/l: 2 points). At 6 months, the consensus was achieved for 76 (95%) patients with 40 in remission (0-1 point), 8 in low disease activity (2-3 points), 16 in moderate disease activity (4-7 points), and 12 in severe disease activity (≥ 8 points). The Still's Disease Activity Score is a valid and sensitive assessment of the disease activity and the therapeutic response in Still's disease, despite its heterogeneous manifestations and patterns with systemic and articular forms. Key Points • The Still's Disease Activity Score (SDAS) is a good simple tool to assess the activity of the disease in a stable state for a week. • The SDAS is developed specifically for Still's disease without the need for an application or a calculator to calculate SDAS in routine clinical practice. • SDAS is a composite score classifying the disease activity in remission, low disease activity, moderate disease activity, and severe disease activity despite its heterogeneous patterns (systemic and articular forms). • The SDAS is a valid, reliable, and sensitive score and can be useful to guide the therapeutic strategy in clinical practice and in research.
Identifiants
pubmed: 39283549
doi: 10.1007/s10067-024-07127-8
pii: 10.1007/s10067-024-07127-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Ruscitti P et al (2024) Recent advances and evolving concepts in Still’s disease. Nat Rev Rheumatol 20:116–132
doi: 10.1038/s41584-023-01065-6
pubmed: 38212542
Bindoli S et al.(2023) Efficacy and safety of therapeutic interventions for the treatment of Still’s disease: a systematic review and meta-analysis informing the EULAR/PReS recommendations for the diagnosis and management of systemic juvenile idiopathic arthritis and adult-onset Still’s disease. Arthritis Rheumatol 75 (Suppl. 9), Abstr. 2569
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430
pubmed: 1578458
Fautrel B, Zing E, Golmard JL, LeMoel G, Bissery A, Rioux C et al (2002) Proposal for a newset of classification criteria for adult-onset still disease. Med (Baltimore) 81:194–200
doi: 10.1097/00005792-200205000-00003
Daghor-Abbaci et al (2023) Proposal of a new diagnostic algorithm for adult onset Still’s disease. Clin Rheumatol 42:1125–1135
doi: 10.1007/s10067-023-06509-8
pubmed: 36694091
Gerfaud-Valentin M, Jamilloux I, Iwaz J, Sève P (2014) Adult onset Still’s disease. Autoimmun Rev 13:708–712
doi: 10.1016/j.autrev.2014.01.058
pubmed: 24657513
Colina M, Zucchini W, Ciancio G, Orzincolo C, Trotta F, Govoni M (2011) The evolution of adult-onset Still’s disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 41:279–285
doi: 10.1016/j.semarthrit.2010.12.006
pubmed: 21377714
Abbaci-Daghor K, Berrah A (2019) Severe destructive arthritis in adult onset Still’s disease. Rheumatol Adv Pract 3(1):rky052. https://doi.org/10.1093/rap/rky052
Munagala R, Misra R, Agarwal V, Lawrence A, Aggarwal A (2012) Adult onset Still’s disease: experience from a tertiary care rheumatology unit. Int J Rheum Dis 15(6):136–141
Hot A, Toh ML, Coppéré B, Perard L, Girard-Madoux MH, Mausservey C et al (2010) Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore) 89:37–46
doi: 10.1097/MD.0b013e3181caf100
pubmed: 20075703
Abbaci Daghor K, Otmane A, Makrelouf M et al (2021) Prognostic factors in adult onset Still’s disease. Arch Rheum & Arthritis Res. 1(5) ARAR.MS.ID.000523. https://doi.org/10.33552/ARAR.2021.01.000523
-Bindoli S et al. Adult‑onset Still’s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options. Drugs. https://doi.org/10.1007/s40265-024-01993
Gabay C, Fautrel B, Rech B, Spertini F, Feist E, Kötter I (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of Tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847
pubmed: 29472362
Ruscitti P, Cipriani P, Masedu F, Lacono D, Ciccia F, Liakouli V (2016) Adult onset Still’s disease : evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three center. Medicine 14:194
pubmed: 27903264
pmcid: 5131497
Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol 37(11):2369–2376
doi: 10.3899/jrheum.100247
pubmed: 20810496
Tibaldi J, Pistzerio A, Aldera E (2020) Development and initial validation of a composite DAS for systemic JIA. Rheumatology 59:3505–3514. https://doi.org/10.1093/rheumatology/keaa240
doi: 10.1093/rheumatology/keaa240
pubmed: 32829413
Macovei LA et al (2022) Adult-onset Still’s disease—a complex disease, a challenging treatment. Int J Mol Sci 23:12810. https://doi.org/10.3390/ijms232112810
doi: 10.3390/ijms232112810
pubmed: 36361602
pmcid: 9655522
Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70:118–136
doi: 10.1097/00005792-199103000-00004
pubmed: 2005777
Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol 14:603–618. https://doi.org/10.1038/s41584-018-0081
doi: 10.1038/s41584-018-0081
pubmed: 30218025
pmcid: 7097309
Daghor-Abbaci K, Ait Hamadouche N, Otmani F et al (2022) Validation of the neutrophil-to-lymphocyte ratio as a new simple biomarker of adult onset Still’s disease. Medicine 101:32
doi: 10.1097/MD.0000000000029970
Leavis HL et al (2023) Management of adult-onset Still’s disease: evidence- and consensus-based recommendations by experts. Rheumatology 00:1–8. https://doi.org/10.1093/rheumatology/kead461
doi: 10.1093/rheumatology/kead461
Schoels et al (2017) Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther 19:155
doi: 10.1186/s13075-017-1346-5
pubmed: 28676129
pmcid: 5496440
Maranini B, Ciancio G, Govoni M (2021) Adult-onset Still’s disease: novel biomarkers of specific subsets, disease activity, and relapsing forms. Int J Mol Sci 22:13320. https://doi.org/10.3390/ijms222413320
doi: 10.3390/ijms222413320
pubmed: 34948117
pmcid: 8706484
Puéchal X, DeBandt M, Berthelot J-M, Breban M, Dubost J-J, Fain O et al (2011) Toci-lizumab in refractory adult Still’s disease. Arthritis Care Res 63:155–159
doi: 10.1002/acr.20319
Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM (2019) Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response. Front Pharmacol 10:296
doi: 10.3389/fphar.2019.00296
pubmed: 31001115
pmcid: 6454864
Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302–308
doi: 10.1136/ard.2007.076034
pubmed: 17947302
Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kaja-lainen A et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra inadult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol 39:2008–11
doi: 10.3899/jrheum.111549
pubmed: 22859346
Piram M, Koné-Paut I, Lachmann HJ et al (2014) Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 73:2168–2173
doi: 10.1136/annrheumdis-2013-203666
pubmed: 24026675
Wallace CA, Giannini EH, Huang B et al (2011) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 63:92936
doi: 10.1002/acr.20497
Kalyoncu U, Kasifoglu T, Omma A et al (2023) Derivation and validation of adult Still Activity Score (SAS). Joint Bone Spine 90:105499
doi: 10.1016/j.jbspin.2022.105499
pubmed: 36423781
Kalyoncu U, Solwaz D, Emmungil H, Yazici A, Kasifoglu T, Kimyon G et al (2016) Response rate of initial conventional treatments, disease course and related factors of patients with adult onset Still disease: data from a large multicenter cohort. J Autoimmun 16:S0896-8411
Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21:53
doi: 10.1186/s13075-019-1838-6
pubmed: 30755262
pmcid: 6373016
Cavalli G, Tomelleri A, De Luca G, Campochiaro C, Dinarello C, Baldissera E, Dagna L (2019) Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 21:54
doi: 10.1186/s13075-019-1843-9
pubmed: 30760322
pmcid: 6375123
Tomaras S, Goetzke CC, Kallinich T, Feist E (2021) Adult-onset Still’s disease: clinical aspects and therapeutic approach. J Clin Med 10:733. https://doi.org/10.3390/jcm10040733
doi: 10.3390/jcm10040733
pubmed: 33673234
pmcid: 7918550